GENEVA, Oct. 9 -- NANJING LEADS BIOLABS CO., LTD. filed a patent application (CN2026/087354) for “ANTI-PD-L1 AND ANTI-4-1BB BISPECIFIC ANTIBODY FOR TREATING MALIGNANT TUMORS AND PHARMACEUTICAL COMBINATION THEREOF”. With publication no. WO/2026/208842, here are the other details related to the patent application:
Kind: Initial Publication with ISR [A1]
IPC: A61K 39/395
Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).
Disclaimer: Curated by HT Syndication....